Rafid Mansour, MD
Internal Medicine · Southfield, MINPI 1265662308
Payments from drug & device makers
Across 76 payments — averaging $35.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$469
- AstraZeneca$312
- Amgen$273
- Pfizer$271
- Boehringer Ingelheim$259
- Novo Nordisk$170
- plus $918 from 14 others
What the payments were for
- Food & beverage$2,57196%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 8 | $469 |
| AstraZeneca | 5 | $312 |
| Amgen | 11 | $273 |
| Pfizer | 12 | $271 |
| Boehringer Ingelheim | 6 | $259 |
| Novo Nordisk | 4 | $170 |
| AbbVie | 3 | $149 |
| Biohaven Pharmaceuticals, Inc. | 2 | $143 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $137 |
| Astellas Pharma US Inc | 3 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $109 |
| Ironwood Pharmaceuticals, Inc | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Genentech USA, Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| GSK | 1 | $18 |
| Novartis | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$250
- NURTEC ODT$125
- ELIQUIS$125
- MOUNJARO$125
- JARDIANCE$124
- ZEPBOUND$121
- TRINTELLIX$109
- TRULANCE$100
How this compares
$2,671 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 115 | $121,297 |
| LinzessLinaclotide | 84 | $68,139 |
| FarxigaDapagliflozin Propanediol | 49 | $62,744 |
| EliquisApixaban | 51 | $62,483 |
| TrulicityDulaglutide | 44 | $41,874 |
| TradjentaLinagliptin | 36 | $35,539 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $29,536 |
| JanuviaSitagliptin Phosphate | 23 | $24,335 |
| MyrbetriqMirabegron | 20 | $22,693 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $14,686 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $14,623 |
| GemtesaVibegron | 14 | $11,830 |
| VascepaIcosapent Ethyl | 11 | $8,205 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 11 | $4,247 |
| Nebivolol Hcl | 49 | $4,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $259 | $156,836151 claims |
| AbbVieLinzess | $149 | $68,13984 claims |
| AstraZenecaFarxiga, Symbicort | $312 | $66,76866 claims |
| PfizerEliquis | $271 | $62,48351 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $18 | $44,15963 claims |
| Lilly USA, LLCTrulicity | $469 | $41,87444 claims |
| Astellas Pharma US IncMyrbetriq | $128 | $22,69320 claims |
| Novo NordiskNovolog Mix 70-30 | $170 | $3,17320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Southfield
- Adam FormanSouthfield$524K
- Talal KhaderSouthfield$319K
- Gregory BergerSouthfield$273K
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.